Oregon Health Sciences University
Oregon Health Sciences University
Portland, Oregon, United States33 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) | PIK3CA-related Overgrowth Spectrum (PROS) | Recruiting | Phase 2 | 2026-10-09 | NCT06997588 | |
| Precision-Based Genomics in Prostate Cancer | Disease Attributes, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, disease susceptibility, inherited disease susceptibility, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Not stated | 2026-10-08 | NCT04706663 | |
| Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease | Bronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Not stated | 2026-10-06 | NCT05919511 | |
| Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events | Arterial Occlusive Diseases, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Atherosclerotic, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Active, not recruiting | Phase 3 | 2026-10-05 | NCT05360446 | |
| CAR-T Long Term Follow Up (LTFU) Study | Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | Recruiting | Phase 3 | 2026-10-02 | NCT02445222 | |
| ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis | eye disorder, retinal degeneration, retinal disorder, retinoschisis | Recruiting | Phase 3 | 2026-09-29 | NCT05878860 | |
| Secukinumab Open Label Roll-over Extension Protocol | Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, immune system disorder | Recruiting | Phase 4 | 2026-09-28 | NCT04638647 | |
| A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | Chronic Disease, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Recruiting | Phase 3 | 2026-09-25 | NCT06868212 | |
| A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Recruiting | Phase 3 | 2026-09-22 | NCT07326709 | |
| Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-09-22 | NCT05201066 | |
| JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization | Aneurysm, abdominal aortic aneurysm, aortic aneurysm, aortic disorder, cardiovascular disorder, vascular disorder | Recruiting | Not applicable | 2026-09-09 | NCT05064540 | |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA | Cerebral Small Vessel Diseases, Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, granulomatosis with polyangiitis, immune system disorder, interstitial lung disease, lung disorder, microscopic polyangiitis, necrotizing vasculitis, nervous system disorder, respiratory system disorder, skin disorder, skin vascular disease, vascular disorder, vasculitis | Active, not recruiting | Phase 2 | 2026-09-04 | NCT06868290 | |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis | Skin and Connective Tissue Diseases, connective tissue disorder, diffuse scleroderma, skin disorder, systemic sclerosis | Active, not recruiting | Phase 2 | 2026-09-02 | NCT06655896 | |
| A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, nephritis, systemic lupus erythematosus, urinary system disorder | Active, not recruiting | Phase 2 | 2026-09-02 | NCT06581198 | |
| A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, acquired idiopathic inflammatory myopathy, autoimmune disease, connective tissue disorder, diffuse scleroderma, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nephritis, nervous system disorder, neuromuscular disease, skin disorder, systemic lupus erythematosus, systemic sclerosis, urinary system disorder | Recruiting | Phase 1 | 2026-08-28 | NCT06925542 | |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | Chromosome Aberrations, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Philadelphia Chromosome, Translocation, Genetic, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2026-08-28 | NCT04971226 | |
| Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Malformations of Cortical Development, Group I, Neoplasms, Multiple Primary, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, central nervous system malformation, cerebral cortical dysplasia, hamartoma, hereditary disease, hereditary neoplastic syndrome, inherited neurodegenerative disorder, neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, tuberous sclerosis, visual epilepsy | Active, not recruiting | Phase 3 | 2026-08-21 | NCT02962414 | |
| Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Tumor Virus Infections, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Active, not recruiting | Phase 1 | 2026-07-28 | NCT05397496 | |
| Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Recruiting | Phase 4 | 2026-07-08 | NCT05548283 | |
| Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Recruiting | Not stated | 2026-07-08 | NCT04509050 | |
| Asciminib Roll-over Study | Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 4 | 2026-07-06 | NCT04877522 | |
| Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis | Recruiting | Phase 1 | 2026-06-30 | NCT06201416 | |
| An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-06-08 | NCT04720157 | |
| North American Prodromal Synucleinopathy Consortium Stage 2 | Lewy body dementia, Parasomnias, Parkinson disease, REM Sleep Parasomnias, REM sleep behavior disorder, autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, dementia, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, parkinsonian disorder, primary dysautonomia, psychiatric disorder, sleep-wake disorder, synucleinopathy | Enrolling by invitation | Not stated | 2026-05-13 | NCT05826457 | |
| Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) | myelodysplastic/myeloproliferative neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-04-21 | NCT04061421 |